---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038533"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:35:17.796311+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports FY 2023 net loss of $8.2M, down from $29.9M; cash runway into Q4 2025

## Summary
- Net loss narrowed to $8.2M in FY 2023 from $29.9M in FY 2022; R&D spend cut to $10.4M from $12.0M.
- Cash and equivalents $15.1M at Dec 31, 2023; company expects funding into Q4 2025 via grant drawdowns.
- First lymphoma patient treated with MT-601 achieved sustained complete response >6 months after CAR T relapse.
- Completed $19M asset sale to Cell Ready reducing annual overhead ~$11M; secured $2M NIH grant for AML program.
- Appointed Juan Vera as CEO/Principal Financial Officer and Monic Stuart as CMO.

## SEC filing metadata
- accession: 0001104659-24-038533
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/0001104659-24-038533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/tm249709d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038533
- JSON: https://secwatch.observer/filing/0001104659-24-038533.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038533.txt

## Key facts
- Earnings Releases
  Marker Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 25, 2024, Marker Therapeutics, Inc. (the “ Company ”) reported financial results for the fiscal year ended December 31, 2023 and other recent corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/0001104659-24-038533-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.